SCHEMBL3017010

SCHEMBL3017010

COc1ccc(Cl)cc1S(=O)(=O)C1CCN(c2nc(-c3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.47
RAB9A P51151 11/20 0.47
NPC1 O15118 9/20 0.47
MAPT P10636 7/20 0.47
L3MBTL1 Q9Y468 2/20 0.42
RECQL P46063 2/20 0.42
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 3/20 0.41
AR P10275 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NTSR1 P30989 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015423 0.95 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3019688 0.94 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3002520 0.92 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3006072 0.92 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3012480 0.91 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3013048 0.90 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3008440 0.90 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3008336 0.90 AR (0.50) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3008094 0.90 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1
SCHEMBL3016836 0.90 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.